IFP Advisors Inc Has $57,000 Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

IFP Advisors Inc lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 24.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 241 shares of the biopharmaceutical company’s stock after acquiring an additional 47 shares during the period. IFP Advisors Inc’s holdings in Alnylam Pharmaceuticals were worth $57,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Huntington National Bank boosted its holdings in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 45 shares during the period. Hollencrest Capital Management acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at about $29,000. R Squared Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $33,000. Washington Trust Advisors Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $42,000. Finally, True Wealth Design LLC grew its position in Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 153 shares during the period. Institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ALNY. Morgan Stanley upped their target price on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Piper Sandler reaffirmed an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Needham & Company LLC reissued a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $310.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $304.26.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. This represents a 81.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Jeffrey V. Poulton sold 967 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the sale, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,986 shares of company stock worth $20,397,849. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $248.13 on Friday. The company has a fifty day moving average price of $254.46 and a two-hundred day moving average price of $261.81. The firm has a market capitalization of $32.12 billion, a PE ratio of -114.35 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.